Commonwealth Equity Services LLC decreased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 7.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,868 shares of the company’s stock after selling 1,827 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Takeda Pharmaceutical were worth $309,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of TAK. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $28,000. Wells Fargo & Company MN increased its stake in shares of Takeda Pharmaceutical by 1.7% in the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after buying an additional 12,756 shares during the period. Aigen Investment Management LP bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $197,000. Catalytic Wealth RIA LLC bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $233,000. Finally, Gold Investment Management Ltd. bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $994,000. Institutional investors own 9.17% of the company’s stock.
Takeda Pharmaceutical Stock Performance
TAK stock opened at $14.91 on Tuesday. The business’s 50-day moving average price is $14.35 and its two-hundred day moving average price is $13.75. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market cap of $47.19 billion, a PE ratio of 27.11, a P/E/G ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.06.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- Learn Technical Analysis Skills to Master the Stock Market
- The Average 401k Balance by Age Explained
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Bank Stocks – Best Bank Stocks to Invest In
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.